SOBI.ST Stock — Price, Charts & Analysis

Swedish Orphan Biovitrum AB (publ) (SOBI.ST) has a trailing P/E of 118.01x and a forward P/E of 29.67x. This places SOBI.ST in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

SOBI.ST trades with 118.01x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether SOBI.ST looks overvalued or undervalued.

SOBI.ST's P/E of 118.01x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

SOBI.ST's trailing EPS is SEK 3.91 and forward EPS is SEK 15.55. Reported earnings growth is 71.60%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Swedish Orphan Biovitrum AB (publ) generated for each share. SOBI.ST's trailing EPS is SEK 3.91, and investors usually prefer EPS that is positive and growing over time.

Swedish Orphan Biovitrum AB (publ) has a market cap of SEK 160.89B, making SOBI.ST a large-cap stock based on the current market value shown on Worldtickers.

SOBI.ST's latest stock price on Worldtickers is SEK 461.40. The latest move is -SEK 4.20 or -0.90%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

SOBI.ST's quote includes a latest price of SEK 461.40. The market open is SEK 467.40. Previous close is SEK 465.60. The intraday range is SEK 456.40 to SEK 469.40.

SOBI.ST is down in the latest quote, with a move of -SEK 4.20 or -0.90%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

SOBI.ST generated SEK 30.62B in trailing revenue. Revenue growth is 27.00%, which helps show whether demand is expanding or slowing.

SOBI.ST's revenue growth is 27.00%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, SOBI.ST shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is SEK 1.38B.

Gross margin is 78.49%. Margins show how efficiently Swedish Orphan Biovitrum AB (publ) turns revenue into profit.

Swedish Orphan Biovitrum AB (publ) carries SEK 17.59B and holds SEK 1.08B in cash.

SOBI.ST holds SEK 1.08B on its balance sheet.

SOBI.ST's book value per share is SEK 121.69.

Institutions hold 75.10% of SOBI.ST shares. Insiders hold 10.05% of shares. Ownership mix helps investors understand how much of Swedish Orphan Biovitrum AB (publ) is held by professional investors and company insiders.

SOBI.ST has 347.29M shares outstanding. Float shares are 223.2M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for SOBI.ST, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for SOBI.ST is SEK 15.55. Earnings growth is 71.60%. Revenue growth is 27.00%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

SOBI.ST's trailing EPS is SEK 3.91. Forward EPS is SEK 15.55. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

SOBI.ST is in the Healthcare sector. Its earnings multiple is 118.01x. Its latest displayed growth metric is 27.00%. Compare these figures with sector peers before deciding whether Swedish Orphan Biovitrum AB (publ) is stronger or weaker than average.

SOBI.ST trades at SEK 461.40. The stock trades at 118.01x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Swedish Orphan Biovitrum AB (publ)'s fundamentals.

SOBI.ST risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.28, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

SOBI.ST should be compared with companies in Drug Manufacturers - Specialty & Generic. Its earnings multiple is 118.01x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Swedish Orphan Biovitrum AB (publ) (SOBI.ST) operates in Healthcare, specifically Drug Manufacturers - Specialty & Generic. Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the

SOBI.ST trades on Stockholm. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

SOBI.ST stock is priced in SEK on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Swedish Orphan Biovitrum AB (publ)'s official website listed on Worldtickers is www.sobi.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Swedish Orphan Biovitrum AB (publ) employs about 2.12K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Swedish Orphan Biovitrum AB (publ) is headquartered in Stockholm, Sweden. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

SOBI.ST is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

SOBI.ST has traded between SEK 262.80 and SEK 487.00 over the past 52 weeks. At SEK 461.40, it is 5.26% below the high and 75.57% above the low. The 52-week range helps gauge long-term price momentum.

SOBI.ST is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is SEK 457.11 and its 200-day moving average is SEK 396.45.

SOBI.ST's RSI is 56.51. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

SOBI.ST's latest RSI reading is 56.51, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for SOBI.ST is near SEK 432.40. Key resistance is near SEK 476.00. Breaks above resistance or below support can change the short-term technical setup.

SOBI.ST's nearest reported support level is SEK 432.40. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

SOBI.ST's nearest reported resistance level is SEK 476.00. A breakout above resistance can improve momentum, especially when volume confirms the move.

SOBI.ST trades about 441.41K shares daily on average. The latest displayed volume is 199.28K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

SOBI.ST's MACD is 1.64, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

SOBI.ST is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 56.51 (neutral). MACD is bullish. Nearest support is around SEK 432.40. Resistance is around SEK 476.00. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is SEK 454.06 (2.54% from price). MA50 is SEK 457.11 (1.86% from price). MA200 is SEK 396.45 (17.44% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. SOBI.ST's MA20 is SEK 454.06. MA50 is SEK 457.11. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

SOBI.ST's pivot is near SEK 461.47. Support is near SEK 432.40. Resistance is near SEK 476.00. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for SOBI.ST is near SEK 451.27. The next upper resistance zone is near SEK 485.70. These levels help define risk and possible follow-through zones after a breakout or breakdown.

SOBI.ST's Bollinger range is roughly SEK 430.78 to SEK 477.34. Band width is near 10.25%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

SOBI.ST's ATR-based typical daily range is about 2.60%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 199.28K shares. Average volume is about 441.41K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

SOBI.ST's all-time high shown on Worldtickers is SEK 487.00. Its all-time low is SEK 10.89. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

SOBI.ST has a beta of 0.28, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.